XM은(는) 미국 국적의 시민에게 서비스를 제공하지 않습니다.

XM은(는) 미국 국적의 시민에게 서비스를 제공하지 않습니다.
G
G

Getinge

뉴스

Reuters - 3 주 전

Anglo American, Rio Tinto, Unilever

EUROPE RESEARCH ROUNDUP-Anglo American, Rio Tinto, Unilever July 23 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Anglo American, Rio Tinto and Unilever, on Tuesday. HIGHLIGHTS * Anglo American Plc AAL.L : HSBC cuts target price to 2,300p from 2,450p * Antofagasta Plc ANTO.L : HSBC raises target price to 1,400p from 1,100p * Belimo Holding AG BEAN.S : Jefferies raises target price to CHF 598 from CHF 498 * Rio Tinto RIO.L : HSBC
A
A
A
B
B
D
E
F
G
G
G
P
T
W
A
A
B
G
R
Reuters - 4 주 전

Barclays, Mips AB, Novo Nordisk

EUROPE RESEARCH ROUNDUP-Barclays, Mips AB, Novo Nordisk July 19 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Barclays, Mips AB and Novo Nordisk on Friday. HIGHLIGHTS * Barclays BARC.L : Jefferies raises target price to 341p from 335p * Mips AB MIPS.ST : Jefferies raises to buy from hold * Novo Nordisk NOVOB.CO : HSBC raises target price to DKK 1150 from DKK 1030 * Spectris SXS.L : HSBC raises target price to 3750p from 3425p * S
A
A
B
B
B
B
B
C
D
E
E
E
G
H
H
H
K
S
S
S
T
A
A
Reuters - 4 주 전

European shares end marginally lower as tech sell-off stymies advances

UPDATE 3-European shares end marginally lower as tech sell-off stymies advances For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window STOXX 600 closes down 0.2% ECB keeps rates unchanged at 3.75% Volvo Cars rise on Q2 adjusted EBIT beat Husqvarna slides on Q2 sales drop Updated at 1600 GMT By Shristi Achar A, Pranav Kashyap and Shashwat Chauhan July 18 (Reuters) - European shares ended lower on Thursday as a continued selloff of chip stocks ke
A
G
H
N
V
E
F
S
G
Reuters - 4 주 전

Getinge rises after Q2 earnings beat

BUZZ-Getinge rises after Q2 earnings beat ** Shares in Getinge GETIb.ST rise around 7% after the Swedish medical equipment maker's Q2 earnings beat expectations ** EBITA, adjusted for items affecting comparability, came in at 981 million Swedish crowns ($93 million) vs analysts' expectations of 829 million crowns ** Group sales came in 4.7% ahead o
G
Reuters - 4 주 전

Medical gear maker Getinge tops Q2 profit forecast as orders grow

UPDATE 3-Medical firm Getinge jumps as rising orders fuel profit beat Adds share move in paragraph 2, analyst comment in -7 By Greta Rosen Fondahn July 18 (Reuters) - Swedish medical equipment maker Getinge GETIb.ST beat second-quarter earnings forecasts on Thursday as its order intake rose despite some problems with its packaging and heart products.
G
Reuters - 4 주 전

Medical gear maker Getinge beats Q2 core profit expectations

Medical gear maker Getinge beats Q2 core profit expectations July 18 (Reuters) - Swedish medical equipment maker Getinge GETIb.ST reported bigger-than-expected core earnings for the second quarter on Thursday, as its order intake grew organically in the period. Reporting by Greta Rosen Fondahn in Gdansk; editing by Milla Nissi
G
Reuters - 1 달 전

Nordic corporate earnings week ahead

DIARY-Nordic corporate earnings week ahead July 12 (Reuters) - Diary of Nordic (OMXS30-SK, OBX-OS, OMXHPI-HE, OMXC20) corporate earnings for the week ahead NORDIC EARNINGS Start Date Start Time (GMT) RIC Company Name Event Name 15-Jul-2024 NTS ORK.OL Orkla ASA Q2 2024 Orkla ASA Earnings Release 17-Jul-2024 05:00 NEL.OL Nel ASA Q2 2024 Nel ASA Earnings Release 18-Jul-2024 NTS TEL.OL Telenor ASA Q2 2024 Telenor ASA Earnings Release 18-Jul-2024 NTS PGS.OL^G24 5088687729 PGS ASA Tgs Newco AS Q2 2024
A
B
D
E
E
E
G
K
K
N
O
P
S
S
T
T
V
W
A
A
S
T
Y
Reuters - 1 달 전

Getinge Extends, Elevates Partnership With Universeum

BRIEF-Getinge Extends, Elevates Partnership With Universeum July 5 (Reuters) - Getinge AB GETIb.ST : EXTENDS AND ELEVATES PARTNERSHIP WITH UNIVERSEUM Further company coverage: [GETIb.ST] (Gdansk Newsroom)
G
Reuters - 2 달 전

Hargreaves Lansdown, Segro, Umicore

EUROPE RESEARCH ROUNDUP-Hargreaves Lansdown, Segro, Umicore June 19 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Hargreaves Lansdown, Segro and Umicore, on Wednesday. HIGHLIGHTS * GEA Group AG G1AG.DE : Jefferies raises to buy from hold * Hargreaves Lansdown HRGV.L : Jefferies cuts to hold from buy * Oxford Instruments OXIG.L : Berenberg raises target price to 2,945p from 2,640p * Segro SGRO.L : Jefferies cuts to hold from buy *
A
A
B
B
B
B
B
B
B
D
D
G
G
G
G
G
H
H
I
K
K
L
M
R
S
S
S
U
U
V
A
S
Reuters - 2 달 전

JPM cuts Getinge's PT by 11% in tough market

BUZZ-JPM cuts Getinge's PT by 11% in tough market ** J.P.Morgan cuts PT for "underweight"-rated Getinge GETIb.ST by 11% to SEK 165 on continued inflationary headwinds on costs, quality challenges and uncertain order development in China ** The Swedish medical equipment maker's shares are down 2.4% at 0753 GMT ** JPM says the Surgical Workflows unit
G
J
Reuters - 2 달 전

Adidas AG, Crest Nicholson Holdings, Standard Chartered

EUROPE RESEARCH ROUNDUP-Adidas AG, Crest Nicholson Holdings, Standard Chartered June 17 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Adidas AG, Crest Nicholson Holdings and Standard Chartered, on Monday. HIGHLIGHTS * Adidas AG ADSGn.DE : JP Morgan raises target price to EUR 250 from EUR 240 * Bellway Plc BWY.L : JP Morgan raises target price to 2,790p from 2,780p * Crest Nicholson Holdings Plc CRST.L : Peel Hunt raises target pr
A
A
B
B
B
C
C
C
E
E
G
H
J
L
O
P
S
S
S
U
A
A
F
U
Reuters - 2 달 전

FDA Identified Getinge's Recall Of Vaporizer Sevoflurane Maquet Filling As Class I Recall

BRIEF-FDA Identified Getinge's Recall Of Vaporizer Sevoflurane Maquet Filling As Class I Recall June 13 (Reuters) - Getinge AB GETIb.ST : FDA:GETINGE RECALLS VAPORIZER SEVOFLURANE MAQUET FILLING FOR RISK OF PATIENT AND HEALTH CARE PROFESSIONAL EXPOSURE TO TOXIC CHEMICAL HYDROGEN FLUORIDE FDA: IDENTIFIED GETINGE'S RECALL OF VAPORIZER SEVOFLURANE MAQ
G
Reuters - 2 달 전

Getinge Granted U.S. FDA 510(K) Clearance For Its Innovative Clinical Decision Support Software Talis +Acg

BRIEF-Getinge Granted U.S. FDA 510(K) Clearance For Its Innovative Clinical Decision Support Software Talis +Acg June 12 (Reuters) - Getinge AB GETIb.ST : GETINGE: GRANTED U.S. FDA 510(K) CLEARANCE FOR ITS INNOVATIVE CLINICAL DECISION SUPPORT SOFTWARE TALIS +ACG Source text for Eikon: [ID:] Further company coverage: [GETIb.ST]
G
Reuters - 3 달 전

Getinge Sees Acute Care Therapies 2024-2028 Net Sales Organic Growth Of 3-5%

BRIEF-Getinge Sees Acute Care Therapies 2024-2028 Net Sales Organic Growth Of 3-5% May 15 (Reuters) - Getinge AB GETIb.ST : GETINGE CEO ON ACUTE CARE THERAPIES UNIT: PROJECTS ORGANIC GROWTH IN NET SALES OF 3-5% IN 2024-2028 GETINGE CEO ON LIFE SCIENCE UNIT: PROJECTS ORGANIC GROWTH IN NET SALES OF 6-10% IN 2024-2028 GETINGE CEO ON SURGICAL WORKFLOWS
G
Reuters - 3 달 전

Getinge heart device quality issues weigh as co issues new outlook target

BUZZ-Getinge heart device quality issues weigh as co issues new outlook target ** Shares in Getinge GETIb.ST fall 8% after the medical equipment maker issues new midterm guidance , but says finances will continue to be negatively impacted by ongoing quality issues with its heart devices until new products are launched ** The company said it targets over 12% growth on average in its adjusted EPS for 2024-2028, compared to its previous target for over 10% growth in EPS for 2022-2025 ** "New mid-te
G
J
Reuters - 3 달 전

Getinge limits sale of heart devices in the US after FDA warning

Getinge limits sale of heart devices in the US after FDA warning May 15 (Reuters) - Sweden's Getinge GETIb.ST will limit sales of some of its heart products in the U.S., the medical equipment maker said late on Tuesday, after recent advice from the U.S. Food and Drug Administration (FDA) to move away from its devices. "We have decided to immediately pause promotional activities of the Cardiohelp System and Cardiosave Intra-Aortic Balloon Pump in the U.S.
G
Reuters - 3 달 전

Getinge Says Financial Target 2024-2028 Is Adjusted EPS Growth Of Above 12% On Average

BRIEF-Getinge Says Financial Target 2024-2028 Is Adjusted EPS Growth Of Above 12% On Average May 14 (Reuters) - Getinge AB GETIb.ST : GETINGE'S FINANCIAL TARGET 2024-2028: ADJUSTED EPS GROWTH OF ABOVE 12% ON AVERAGE FOR 2024, GETINGE REPEATS ITS GUIDANCE OF 2-5% ORGANIC GROWTH IN NET SALES AND 3-5% GROWTH FROM ACQUIRED UNITS DOES NOT PROVIDE ANY AN
G

조건

인기 자산

면책조항: XM Group 회사는 체결 전용 서비스와 온라인 거래 플랫폼에 대한 접근을 제공하여, 개인이 웹사이트에서 또는 웹사이트를 통해 이용 가능한 콘텐츠를 보거나 사용할 수 있도록 허용합니다. 이에 대해 변경하거나 확장할 의도는 없습니다. 이러한 접근 및 사용에는 다음 사항이 항상 적용됩니다: (i) 이용 약관, (ii) 위험 경고, (iii) 완전 면책조항. 따라서, 이러한 콘텐츠는 일반적인 정보에 불과합니다. 특히, 온라인 거래 플랫폼의 콘텐츠는 금융 시장에서의 거래에 대한 권유나 제안이 아닙니다. 금융 시장에서의 거래는 자본에 상당한 위험을 수반합니다.

온라인 거래 플랫폼에 공개된 모든 자료는 교육/정보 목적으로만 제공되며, 금융, 투자세 또는 거래 조언 및 권고, 거래 가격 기록, 금융 상품 또는 원치 않는 금융 프로모션의 거래 제안 또는 권유를 포함하지 않으며, 포함해서도 안됩니다.

이 웹사이트에 포함된 모든 의견, 뉴스, 리서치, 분석, 가격, 기타 정보 또는 제3자 사이트에 대한 링크와 같이 XM이 준비하는 콘텐츠 뿐만 아니라, 제3자 콘텐츠는 일반 시장 논평으로서 "현재" 기준으로 제공되며, 투자 조언으로 여겨지지 않습니다. 모든 콘텐츠가 투자 리서치로 해석되는 경우, 투자 리서치의 독립성을 촉진하기 위해 고안된 법적 요건에 따라 콘텐츠가 의도되지 않았으며, 준비되지 않았다는 점을 인지하고 동의해야 합니다. 따라서, 관련 법률 및 규정에 따른 마케팅 커뮤니케이션이라고 간주됩니다. 여기에서 접근할 수 있는 앞서 언급한 정보에 대한 비독립 투자 리서치 및 위험 경고 알림을 읽고, 이해하시기 바랍니다.

리스크 경고: 고객님의 자본이 위험에 노출 될 수 있습니다. 레버리지 상품은 모든 분들에게 적합하지 않을수 있습니다. 당사의 리스크 공시를 참고하시기 바랍니다.